Topics

Gliomas | Treatment | Immunotherapy | Vaccines

Home > Publications > Topics > Gliomas > Treatment > Immunotherapy > Vaccines

Amanzadeh Jajin E, Oraee Yazdani S, Zali A, Esmaeili A.
Efficacy and Safety of Vaccines After Conventional Treatments for Survival of Gliomas: A Systematic Review and Meta-Analysis.
Oncol Rev. 2024 Apr 19;18:1374513. doi: 10.3389/or.2024.1374513. PMID: 38707486. Review; Meta-Analysis. ˍ

Zhao B, Yao L, Hatami M, Ma W, Skutella T.
Vaccine-based immunotherapy and related preclinical models for glioma.
Trends Mol Med. 2024 Jul 15:S1471-4914(24)00167-9. doi: 10.1016/j.molmed.2024.06.009. PMID: 39013724. Review. ˍ

*Phung LH, Nejo T, Okada H.
Lessons from Post-Immunotherapy Tumor Tissues in Clinical Trials: How Can We Fuel the Tumor Microenvironment in Gliomas?
Vaccines (Basel). 2024 Aug 1;12(8):862. doi: 10.3390/vaccines12080862. PMID: 39203988. Review. ˍ

Mao M, Yang W, Zhang X.
Current mRNA-Based Vaccine Strategies for Glioma Treatment.
Crit Rev Oncol Hematol. 2024 Aug 7:104459. doi: 10.1016/j.critrevonc.2024.104459. PMID: 39097247. Review˰ ˍ

Andrew Awuah W, Shah MH, Tan JK, Ranganathan S, Sanker V, Darko K, Tenkorang PO, Adageba BB, Ahluwalia A, Shet V, Aderinto N, Kundu M, Abdul-Rahman T, Atallah O.
Immunotherapeutic advances in glioma management: The rise of vaccine-based approaches.
CNS Neurosci Ther. 2024 Aug 30;30(9):e70013. doi: 10.1111/cns.70013. PMID: 39215399. Review. ˍ

Zhang T, Jiang S, Zhang L, Liu Y, Zheng H, Zhao H, Du S, Xu Y, Lu X.
A bibliometric analysis of oncolytic virotherapy combined with immunotherapy.
Hum Vaccin Immunother. 2024 Oct 14;20(1):2406621. doi: 10.1080/21645515.2024.2406621. PMID: 39400287. Bibliometric analysis. ˍ

Zelba H, Shao B, Rabsteyn A, Reinhardt A, Greve C, Oenning L, Kayser S, Kyzirakos C, Latzer P, Riedlinger T, Bartsch O, Wünsche J, Harter J, Feldhahn M, Bantel Y, Johänning J, Ködding J, Hadaschik D, Schulze M, Battke F, Maksimovic O, Scheble V, Miller AM, Castro M, Blumenthal DT, Glas M, Reardon D, Biskup S.
In-depth characterization of vaccine-induced neoantigen-specific T cells in patients with IDH1-mutant glioma undergoing personalized peptide vaccination.
J Immunother Cancer. 2025 Jun 5;13(6):e011070. doi: 10.1136/jitc-2024-011070. PMID: 40480654. Translational study. ˍ